Could a common asthma drug help with a rare muscle disease? new study launches.
NCT ID NCT06721299
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing whether clenbuterol, a drug used for breathing problems, is safe for people with facioscapulohumeral muscular dystrophy (FSHD). About 30 adults with FSHD will receive one of three doses of the drug. Researchers will monitor side effects, heart rate, blood pressure, and lab values to find a dose that people can tolerate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kansas Medical Center
RECRUITINGKansas City, Kansas, 66160, United States
-
University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
-
University of Washington
RECRUITINGSeattle, Washington, 98104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for FSHD: Long-Term drug safety trial underway
- New hope for FSHD: experimental drug AOC 1020 completes early testing
- New study aims to sharpen tools for testing kids with rare muscle disease
- FSHD patients unite: new registry aims to accelerate research and care
- New hope for rare muscle disease: experimental drug enters human trials